MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Archives of cancer-blog


Go Back to the main cancer-blog

Subscribe To Health Blog RSS Feed  RSS content feed What is RSS feed?

Archives Of Cancer-blog From Medicineworld.Org


October 17, 2007, 4:47 AM CT

Gold nanorods to fighting cancer

Gold nanorods to fighting cancer
Scientists have shown how tiny "nanorods" of gold can be triggered by a laser beam to blast holes in the membranes of tumor cells, setting in motion a complex biochemical mechanism that leads to a tumor cell's self-destruction.

Tumor cell membranes often have an abnormally high number of receptor sites to capture molecules of folic acid, or folate, a form of vitamin B that a number of tumor cells crave. The Purdue scientists attached folate to the gold nanorods, enabling them to target the receptors and attach to the tumor cell membranes.

"The cells are then illuminated with light in the near-infrared range," said Ji-Xin Cheng (pronounced Gee-Shin), an assistant professor in Purdue's Weldon School of Biomedical Engineering. "This light can easily pass through tissue but is absorbed by the nanorods and converted rapidly into heat, leading to miniature explosions on the cell surface".

Researchers have recently determined that gold nanorods and other nanostructures can be used to target and destroy tumor cells, but it was generally assumed that cell death was due to the high heat produced by the light-absorbing nanoparticles. The Purdue team discovered, however, that a more complex biochemical scenario is responsible for killing the cells.

"We have observed that rather than cooking the cells to death, the nanorods first punch holes in the membrane, and cell death is then chemically induced, in this case by an influx of calcium," said Alexander Wei, an associate professor of chemistry at Purdue.........

Posted by: Janet      Read more         Source


October 15, 2007, 6:19 PM CT

Cancer death rate decline doubling

Cancer death rate decline doubling
A new report from the nations leading cancer organizations shows cancer death rates decreased on average 2.1 percent per year from 2002 through 2004, nearly twice the annual decrease of 1.1 percent per year from 1993 through 2002. The findings are in the Annual Report to the Nation on the Status of Cancer, 1975-2004, Featuring Cancer in American Indians and Alaska Natives published online October 15, 2007 (www.interscience.wiley.com/cancer/report2007) and appearing in the November 15, 2007, issue of Cancer.

A featured special section provides the most comprehensive cancer data to date for American Indians and Alaska Natives (AI/AN) across the United States. Cancer incidence rates among AI/AN men and women varied two hundred percent among six geographic regions of the country. From 1999 through 2004, AI/AN men from the Northern Plains region and AI/AN women from Alaska and the Northern and Southern Plains regions had higher cancer incidence rates than non-Hispanic white (NHW) men and women in the same areas.

Among the general population, the report suggests that long-term declines in cancer death rates continued through 2004 for both sexes and, despite overall higher death rates for men, the declines from 2002 through 2004 were 2.6 percent per year among men and 1.8 percent per year among women. Death rates decreased for the majority of the top 15 cancers in men and women. Important declines were noted for the three leading causes of cancer deaths in men: lung, prostate and colorectal cancers. In women, deaths rates from colorectal cancer and breast cancer decreased, while the rate of increase for lung cancer deaths slowed substantially.........

Posted by: Janet      Read more         Source


October 15, 2007, 4:43 PM CT

First colonoscopy with removal of polyps

First colonoscopy with removal of polyps
Using a model to predict reductions in death from colorectal cancer, epidemiologists and clinical scientists from Memorial Sloan-Kettering looked at the relative effect of an initial screening colonoscopy which clears pre-malignant polyps from the colon versus surveillance follow-up colonoscopy. Ann G. Zauber, Ph.D., Sidney J. Winawer, M.D., MACG and his colleagues presented their findings at the Annual Scientific Meeting of the American College of Gastroenterology.

The model demonstrated a dramatic reduction in expected colorectal cancer mortality with initial polypectomy with or without surveillance, and suggests that the initial polypectomy accounts for the major component of the mortality reduction, explained Dr. Zauber.

Using a MISCAN model, scientists used National Polyp Study data to predict colorectal cancer mortality among three groups of patients: those with no initial removal of polyps or follow-up surveillance by colonoscopy, in comparison to patients with only initial polypectomy, and those with both polypectomy and follow-up surveillance. The model predicted mortality of up to thirty years after the initial colorectal exam and removal of pre-malignant polyps.

As per Dr. Zauber, the major effect on colorectal cancer mortality reduction produced by the initial polypectomy rather than the surveillance colonoscopies is consistent with the low occurence rate of advanced adenomas observed during National Polyp Study (NPS) follow-up (i.e., pre-malignant growths in the colon larger than 1 cm, polyps with a villous component, high grade dysplasia or invasive colorectal cancer.)........

Posted by: Sue      Read more         Source


October 12, 2007, 5:09 AM CT

Molecules that block cancer cells from modifying cell DNA

Molecules that block cancer cells from modifying cell DNA
Scientists have discovered new small molecules that may prevent prostate cancer cells from turning off normal genes in a process that transforms normal cells into cancer cells. This significant discovery in the field of epigenetics has immediate implications in the development of new diagnostic tests and cancer medications. The findings were presented today at the Prostate Cancer Foundations annual Scientific Retreat. Funding for the research was provided by the Prostate Cancer Foundation, as well as from the National Cancer Institute and the Avon Foundation.

Epigenetics refers to changes to genes other than changes to the DNA sequence itself, such as the addition of molecules to the DNA strand. While the development of cancer can arise from defective or mutated genes, it can also arise from these changes that can actually prevent a cell from acting as it should. Cancer cells exploit this process, putting some genes in cold storage or turned off by modifying the cell DNA in a process known as methylation.

Lead researcher William Nelson, M.D., Ph.D., Professor of Oncology and Urology at the Johns Hopkins Kimmel Cancer Center, explained the findings. One of the proteins in the cell that triggers this process is called a methyl-CpG binding protein, or MBD. We have discovered an antagonist of MBD2 that keeps this protein from binding to methylated genes. If the protein cant bind to the gene, then it cant keep the gene turned off and the gene is turned back on able to act in the way it is supposed to.........

Posted by: Janet      Read more         Source


October 11, 2007, 10:29 PM CT

Why some prostate cancer recurs after treatment

Why some prostate cancer recurs after treatment
Cancer scientists have long worked to understand why some prostate cancers recur after the use of therapies designed to stop the production of testosterone and other androgens that fuel cancer cell growth. New research has now detected that androgen-synthesizing proteins are present within cancer cells, which suggests that cancer cells may develop the capacity to produce their own androgens.

The presence of these proteins may explain why some prostate cancers become resistant to these widely-used therapies, and offers new directions for research into future therapys that could block the development of androgens in the cancer cells. The study, funded by the Prostate Cancer Foundation and the National Cancer Institute, was presented today at the Foundations annual Scientific Retreat.

Androgen-deprivation treatment is routinely used in the therapy of advanced (metastatic) prostate cancer, in order to deprive cancer cells of these hormones that fuel their growth. However, over time cancer cells can become androgen independent, and grow even in the presence of these medications. This type of the cancer is a lethal form of the disease, with most patients dying 18 to 24 months after becoming resistant to hormone suppression. Research in the field has focused on understanding the mechanisms used by these cancer cells to become castration resistant.........

Posted by: Mark      Read more         Source


October 10, 2007, 5:49 PM CT

Obesity boosts oesophageal cancer

Obesity boosts oesophageal cancer
Obese people are six times as likely to develop gullet (oesophageal) cancer as people of healthy weight, shows research published ahead of print in the journal Gut.

Rates of oesophageal cancer have been rising rapidly, and in some countries, they have risen faster than those of every other major cancer, say the authors.

The findings are based on a comparison of almost 800 people with oesophageal cancer and almost 1600 randomly selected people eligible to vote, who did not have the disease.

Men and those under the age of 50 were particularly vulnerable, the findings showed.

The link between acid reflux and gullet cancer is well known, and unsurprisingly, repeated symptoms of severe heartburn or gastrointestinal reflux disease (GORD) were linked to a much higher risk of the cancer.

And the more frequent the symptoms, the greater was the likelihood of having oesophageal cancer.

GORD quintupled the risk of oesophageal cancer, and a combination of obesity and acid reflux boosted the chances of having it by a factor of 16.

But people who were clinically obese had a much higher risk of oesophageal cancer than those whose weight was in the healthy range, regardless of whether they had reflux disease or not.

Those with a body mass index (BMI) of 40 or more were six times as likely to have the cancer as those with a BMI between 18.5 and 25.........

Posted by: Sue      Read more         Source


October 10, 2007, 5:10 AM CT

Prostate cancer more likely to return in blacks

Prostate cancer more likely to return in blacks
African-American men are more likely to have their prostate cancer return after therapy, but their disease is no more aggressive when it does recur than that of their white counterparts, as per a research studyled by Duke Prostate Center researchers.

Our study observed that African-American men have a slightly higher risk of what is known as PSA recurrence, which is a blood test that indicates the presence of cancer based on the levels of a certain biomarker known as prostate-specific antigen, said Stephen Freedland, M.D., a urologist at Duke and senior researcher on the study. We were encouraged, however, to see that their disease is not necessarily more aggressive than that of white men, once it has recurred.

African-American men tend to have higher PSA levels at initial diagnosis of prostate cancer, as well, despite being diagnosed at younger ages. This suggests that there may be an underlying genetic and biologic component that predisposes African-American men to prostate disease, Freedland said, highlighting the need for black men to have prostate screening early and often.

The team's findings would be reported in the November 15, 2007 print edition of the journal Cancer, but also appeared early in the journals September 17, 2007 online edition. The study was funded by the U.S. Department of Defense, the Prostate Cancer Research Program, the Department of Veterans Affairs, the National Institutes of Health, the Georgia Cancer Coalition and the American Urological Association Foundation.........

Posted by: Mark      Read more         Source


October 10, 2007, 4:47 AM CT

New radioactive agents for colon cancer work inside cells

New radioactive agents for colon cancer work inside cells
Johns Hopkins researchers have developed a potentially novel way to fight colorectal cancer using tiny molecules to deliver potent barrages of radiation inside cancer cells, unlike current therapys that bind to the surface of cells and attack from the outside and cause unwanted side effects.

In laboratory studies with normal and cancer cells, the new radiation delivery system proved able to specifically target colon cancer cells, and whats left over is likely to be easily filtered out by the kidneys because the delivery systems molecules are so small.

As reported online in PLoS One on October 3, Hopkins colorectal cancer specialists John Abraham, Ph.D., and Stephen Meltzer, M.D. -working with the notion that small molecules generally make better therapy packages-designed small bits of protein only 10 amino acids long as the foundation for their drugs. By contrast, antibodies used to deliver radiation or chemicals can be over one thousand amino acids long.

The team attached radioactive phosphorous, P32, as a test of how well their peptides worked and to our surprise, our first tests showed that cells were ingesting these molecules, thus transferring the radiation inside and killing them by breaking up their DNA and proteins, Abraham says.

While cautioning that the new radiation delivery system is still far from ready for use in people, Abraham notes that P32 gives off high energy that can penetrate through 5 millimeters of human tissue, making it a good candidate to tackle colon cancer since colon cancer cells can often form large, thick tumors into which drugs may not penetrate very well. In addition, P32-labeled peptides may serve another valuable use: to find small metastases or recurrences of colon tumors while they are still small enough to treat. Images of the body can be taken of the labeled peptides as they bind, revealing where stray tumor cells may be nesting.........

Posted by: Sue      Read more         Source


October 9, 2007, 8:55 PM CT

Low-Fat Dietary To Lower Risk of Ovarian Cancer

Low-Fat Dietary To Lower Risk of Ovarian Cancer
A diet low in fat could reduce the risk of ovary cancer in healthy postmenopausal women, as per new results from the Women's Health Initiative (WHI) Dietary Modification Trial. Scientists observed that after four years, women who decreased the amount of dietary fat they consumed were 40 percent less likely to develop ovary cancer than women who followed normal dietary patterns. As expected, no effect was found during the first four years because preventive benefits on cancer often take a number of years to develop. Ovary cancer affects about 1 in 60 U.S. women in their lifetimes and has the highest mortality of all cancers of the female reproductive system.

"Low-Fat Dietary Pattern and Invasive Cancer Incidence: Further Results from the Women's Health Initiative Dietary Modification Trial," is published online October 9 by the Journal of the National Cancer Institute. The WHI Dietary Modification Trial was conducted in 40 clinical centers throughout the United States and is funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.

The WHI Dietary Modification clinical trial followed 48,835 healthy, postmenopausal women for an average of 8.1 years to test whether a low-fat diet would reduce the risk of cancer and cardiovascular disease. Nearly 20,000 women in the intervention group were counseled to decrease fat intake to 20 percent of calories and to replace calories from fat with calories from vegetables, fruits, and grains. The control group (nearly 30,000 women) received diet-related education materials only.........

Posted by: Emily      Read more         Source


October 8, 2007, 11:20 AM CT

Apatone for cancer treatment

Apatone for cancer treatment
In a significant advancement in the ongoing battle against cancer, a group of scientists from Summa Health System, IC-MedTech and other institutions have completed the first ever FDA-approved human clinical trial of Apatone. Demonstrating promising results, Apatone exploits a new strategy to selectively lower the level of compounds within tumor cells that assist in energy production and protect against chemotherapy. This non-toxic approach weakens and kills cancers in a novel way.

Apatone was discovered by Dr. Henryk Taper from the Catholic University of Leuven in Brussels, Belgium and was developed by Dr. James Jamison and Dr. Jack Summers, both of Summa Health System, and Dr. Jacques Gilloteaux, now with the American University of the Caribbean in St. Maarten. Their groundbreaking discovery observed that moderate doses of Apatone eliminate a number of types of cancer cells, including prostate, bladder, renal and ovarian.

This strategy targets cancer cells by their inflammatory response, explains Dr. Jamison. Its a different approach than most other anti-tumor drugs, which target dividing cells or the development of blood vessels within the tumor. Since normal cells use sugars or fats for energy and cancer cells rely on glucose, the real key here is that Apatone resembles glucose. As Apatone preferentially accumulates in cancer cells, it also supplies quinone that weakens and can destroy the cancer cell from within.........

Posted by: Janet      Read more         Source



Older Blog Entries   1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27   28   29   30   31   32   33   34   35   36   37   38   39   40   41   42   43   44   45   46   47   48   49   50   51   52   53   54   55   56   57   58   59   60   61   62   63   64   65   66   67   68  

Cancer
Cancer is a very common disease, approximately one out of every two American men and one out of every three American women will have some type of cancer at some point during the course of their life. Cancer is more common in the elderly and 77 percent of cancers occur in people above age 55 or older. Cancer is also common in children. Cancer incidence is said to have two peaks once during early childhood and then during late years in life. No age period is completely exempted from development of cancers. Some cancers occur predominantly in the elderly, other types occur in children, Cancer occurs in all ethnic races, however the cancer rates and rates of specific cancer types may vary from group to group. Late stages of cancer may be incurable in most cases, but with the advancement of medicine, more and more cancers are becoming curable.

Medicineworld.org: Archives of cancer-blog

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.